FDA Commissioner Robert Califf, MD, talked to Cardiovascular Business about healthcare spending, inconsistent patient outcomes and much more.

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Back in 2019, the FDA issued a warning about the use of paclitaxel-coated devices when treating peripheral artery disease. The agency took back that warning in 2023, but it appears to have made a significant impact on patient care. 

The care team behind the very first robotic aortic valve replacement and coronary artery bypass surgery has written about the experience in The Annals of Thoracic Surgery. The group discussed the development of the technique, how the patient was chosen for treatment and other key details.

The heightened risks were even seen in women who were never diagnosed with a psychiatric disorder. It remains unclear why the same trend was not seen in men.

One study presented during the three-day conference focused on the potential benefits of an optimized TAVR pathway. Another study, meanwhile, tracked changes in paravalvular leak severity over time.

Intravascular lithotripsy is still a safe and effective frontline preparation tool when PCI patients present with calcified nodules, a new two-year study confirmed. Researchers focused on stent expansion and luminal gain, among other key data points.

Gilbert Tang, MD, surgical director of the structural heart program at the Mount Sinai Health System, discussed a key challenge care teams often encounter during tricuspid valve procedures.